WO2005113813A8 - Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics - Google Patents

Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics

Info

Publication number
WO2005113813A8
WO2005113813A8 PCT/US2005/014361 US2005014361W WO2005113813A8 WO 2005113813 A8 WO2005113813 A8 WO 2005113813A8 US 2005014361 W US2005014361 W US 2005014361W WO 2005113813 A8 WO2005113813 A8 WO 2005113813A8
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulin
nucleic acid
atopic disease
acid ligands
ligands specific
Prior art date
Application number
PCT/US2005/014361
Other languages
French (fr)
Other versions
WO2005113813A3 (en
WO2005113813A2 (en
Inventor
Sharon Cload
John L Diener
Sara Chesworth Keene
Markus Kurz
H A Daniel Lagasse
Harold Nicholas Marsh
Pooja Sawhney
Original Assignee
Archemix Corp
Sharon Cload
John L Diener
Sara Chesworth Keene
Markus Kurz
H A Daniel Lagasse
Harold Nicholas Marsh
Pooja Sawhney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp, Sharon Cload, John L Diener, Sara Chesworth Keene, Markus Kurz, H A Daniel Lagasse, Harold Nicholas Marsh, Pooja Sawhney filed Critical Archemix Corp
Priority to EP05779587A priority Critical patent/EP1742959A2/en
Priority to JP2007510909A priority patent/JP2007534339A/en
Priority to AU2005245793A priority patent/AU2005245793A1/en
Priority to CA002564311A priority patent/CA2564311A1/en
Publication of WO2005113813A2 publication Critical patent/WO2005113813A2/en
Publication of WO2005113813A8 publication Critical patent/WO2005113813A8/en
Publication of WO2005113813A3 publication Critical patent/WO2005113813A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/331—Universal or degenerate base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses aptamers capable of binding to Immunoglobulin E (“IgE”) useful as therapeutics in and diagnostics of atopic disease and/or other diseases or disorders in which IgE has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to IgE.
PCT/US2005/014361 2004-04-26 2005-04-26 Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics WO2005113813A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP05779587A EP1742959A2 (en) 2004-04-26 2005-04-26 Nucleic acid ligands to immunoglobulin e and their use as atopic disease therapeutics
JP2007510909A JP2007534339A (en) 2004-04-26 2005-04-26 Nucleic acid ligands specific for immunoglobulin E and their use as atopic disease treatment
AU2005245793A AU2005245793A1 (en) 2004-04-26 2005-04-26 Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics
CA002564311A CA2564311A1 (en) 2004-04-26 2005-04-26 Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US56560104P 2004-04-26 2004-04-26
US60/565,601 2004-04-26
US57412004P 2004-05-24 2004-05-24
US60/574,120 2004-05-24
US58186504P 2004-06-22 2004-06-22
US60/581,865 2004-06-22
US66020405P 2005-03-07 2005-03-07
US60/660,204 2005-03-07

Publications (3)

Publication Number Publication Date
WO2005113813A2 WO2005113813A2 (en) 2005-12-01
WO2005113813A8 true WO2005113813A8 (en) 2006-03-09
WO2005113813A3 WO2005113813A3 (en) 2006-08-24

Family

ID=35428939

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/014361 WO2005113813A2 (en) 2004-04-26 2005-04-26 Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics

Country Status (6)

Country Link
EP (1) EP1742959A2 (en)
JP (1) JP2007534339A (en)
KR (1) KR20070044813A (en)
AU (1) AU2005245793A1 (en)
CA (1) CA2564311A1 (en)
WO (1) WO2005113813A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5135578B2 (en) * 2007-02-20 2013-02-06 国立大学法人金沢大学 Magnetic resonance measuring apparatus, integrated circuit, and magnetic resonance measuring method
EP2730915A4 (en) * 2011-07-04 2015-06-17 Nec Solution Innovators Ltd Method for evaluating redox activity of nucleic acid molecule, and nucleic acid molecule having redox activity
KR20220139425A (en) 2012-07-13 2022-10-14 웨이브 라이프 사이언시스 리미티드 Chiral control

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766853A (en) * 1990-06-11 1998-06-16 Nexstar Pharmaceuticals, Inc. Method for identification of high affinity nucleic acid ligands to selectins
US5629155A (en) * 1990-06-11 1997-05-13 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US6841539B1 (en) * 1998-05-21 2005-01-11 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
WO2003102212A2 (en) * 2002-05-31 2003-12-11 Regents Of The University Of Minnesota In vitro evaluation of nucleic acid ligands
EP1552002A4 (en) * 2002-06-18 2006-02-08 Archemix Corp Aptamer-toxin molecules and methods for using same
ATE516366T1 (en) * 2002-07-25 2011-07-15 Archemix Corp REGULATED APTAMER THERAPEUTICS
US9303262B2 (en) * 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators

Also Published As

Publication number Publication date
JP2007534339A (en) 2007-11-29
AU2005245793A1 (en) 2005-12-01
EP1742959A2 (en) 2007-01-17
CA2564311A1 (en) 2005-12-01
KR20070044813A (en) 2007-04-30
WO2005113813A3 (en) 2006-08-24
WO2005113813A2 (en) 2005-12-01
AU2005245793A2 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
WO2006033854A3 (en) Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
WO2007025049A3 (en) Aptamers that bind thrombin with high affinity
WO2005079363A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
WO2006029258A3 (en) Aptamer medicinal chemistry
WO2010033279A3 (en) Antibodies with altered binding to fcrn and methods of using same
WO2006088888A3 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
WO2008116149A3 (en) Apoptotic anti- ige antibodies binding the membrane-bound ige
HK1222870A1 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r il-22 il-22r
WO2007092640A3 (en) Antibodies that bind par-2
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2007024715A3 (en) Dual variable domain immunoglobin and uses thereof
WO2006003388A3 (en) Compositions and methods for treating inflammatory disorders
WO2007045477A3 (en) Human antibodies against il-13 and therapeutic uses
WO2008097461A3 (en) Hepcidin and hepcidin antibodies
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
WO2008024188A3 (en) Dual variable domain immunoglobulin and uses thereof
WO2007042573A3 (en) Compositions and methods for treating proliferative disorders
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2008008359A3 (en) Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor
IL198379A (en) Humanized antibodies and antibody fragments that specifically bind sphingosine-1-phosphate, nucleic acids encoding the same and compositions and methods for use thereof to treat disease
WO2008123999A3 (en) Anti-ige antibodies
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
WO2007042261A3 (en) Compositions comprising cross-species-specific antibodies and uses thereof
MX2009013824A (en) Antigen binding proteins that bind par-2.
WO2006096222A3 (en) Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

WWE Wipo information: entry into national phase

Ref document number: 2564311

Country of ref document: CA

Ref document number: 2007510909

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 6413/DELNP/2006

Country of ref document: IN

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005245793

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005779587

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020067024878

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2005245793

Country of ref document: AU

Date of ref document: 20050426

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005245793

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580021366.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005779587

Country of ref document: EP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)